Please use this identifier to cite or link to this item:
|Title:||The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study|
|Authors:||Roach, Paul J;Francis, Roslyn ;Emmett, Louise ; Hsiao, Edward; Kneebone, Andrew; Hruby, George;Eade, Thomas ;Nguyen, Quoc A ;Thompson , Benjamin D ;Cusick , Thomas ;McCarthy, Michael ;Tang, Colin ;Ho, Bao ;Stricker, Philip D ;Scott , Andrew M|
|Citation:||Journal of Nuclear Medicine 2017; online first: 23 June|
|Abstract:||68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging impacts on management intent in patients with primary or recurrent prostate cancer. Methods: Prior to undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow up questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether their management plan would change. Results: A total of 431 patients with prostate cancer from four Australian centers had pre- and post-68Ga-PSMA management plans completed. Scans were performed for primary staging of intermediate and high risk disease in 25% patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure post definitive surgery and /or radiation treatment (62% change in management intent) compared with patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39% and distant metastatic disease in 16% of patients. Conclusion:68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. This demonstrates the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.|
|Type of Clinical Study or Trial:||Multicentre Studies|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.